Advertisement

Investigational New Drugs

, Volume 22, Issue 1, pp 27–37 | Cite as

Recent Advances in Brain Tumor Therapy: Local Intracerebral Drug Delivery by Polymers

  • Christopher Guerin
  • Alessandro Olivi
  • Jon D. Weingart
  • H. Christopher Lawson
  • Henry Brem
Article

Abstract

New approaches to malignant glioma are being actively investigated. Local drug delivery directly to the site of the tumor is one novel approach that has been approved by the US FDA and other regulatory agencies worldwide. This agent, Gliadel®, delivers the chemotherapeutic drug carmustine (BCNU) from a biodegradable polymer placed in the resection cavity after brain tumor surgery. Gliadel® represents the first clinical application of polymer delivery for brain tumors, but the potential for this new methodology is far greater. In this review, we will briefly summarize the development of Gliadel® from a laboratory idea to its current role as an approved treatment for gliomas. Then we will present the most recent work being done to expand the potential benefits of polymeric delivery for brain tumors. This work includes trials for its use as the initial therapy for gliomas, as well as its use against metastasis. Further clinical trials exploring the maximum-tolerated dose and the combination of Gliadel® with systemic chemotherapeutic treatments such as temozolamide and O6–benzylguanine will be reviewed. Finally, we will present preclinical work on the efficacy of polymeric methods for delivering other chemotherapeutic agents, and a variety of novel compounds that modify brain tumor biology. This latter work represents potential future clinical applications of local polymeric drug delivery to the brain and other sites where cancers can occur.

interstitial therapy Gliadel® angiogenesis chemotherapy immunotherapy radiosensitizers 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Brem H, Langer R: Polymer-based drug delivery to the brain. Sci Med July/August 3(4): 52–61, 1996Google Scholar
  2. 2.
    Black P: Brain tumors. Part 1 [see comments]. N Engl J Med 324(21): 1471–1476, 1991Google Scholar
  3. 3.
    Hochberg FH, Pruitt A: Assumptions in the radiotherapy of glioblastoma. Neurology 30(9): 907–911, 1980Google Scholar
  4. 4.
    Tamargo RJ, Epstein JI, Reinhard CS, Chasin M, Brem H: Brain biocompatibility of a biodegradable, controlled-release polymer in rats. J Biomed Mater Res 23(2): 253–266, 1989Google Scholar
  5. 5.
    Brem H, Tamargo RJ, Olivi A, Pinn M, Weingart JD, Wharam M, Epstein JI: Biodegradable polymers for controlled delivery of chemotherapy with and without radiation therapy in the monkey brain. J Neurosurg 80(2): 283–290, 1994Google Scholar
  6. 6.
    Grossman SA, Reinhard C, Colvin OM, Chasin M, Brundrett R, Tamargo RJ, Brem H: The intracerebral distribution of BCNU delivered by surgically implanted biodegradable polymers. J Neurosurg 76(4): 640–647, 1992Google Scholar
  7. 7.
    Fung L, Ewend M, Sills A, Sipos E, Thompson R, Watts M, Colvin O, Brem H, Saltzman W: Pharmacokinetics of interstitial delivery of carmustine, 4-hydroperoxycyclophosphamide, and paclitaxel from a biodegradable polymer implant in the monkey brain. Cancer Res 58(4): 672–684, 1998Google Scholar
  8. 8.
    Tamargo RJ, Myseros JS, Epstein JI, Yang MB, Chasin M, Brem H: Interstitial chemotherapy of the 9L gliosarcoma: Controlled release polymers for drug delivery in the brain. Cancer Res 53(2): 329–333, 1993Google Scholar
  9. 9.
    Brem H, Mahaley MS Jr, Vick NA, Black KL, Schold SC Jr, Burger PC, Friedman AH, Ciric IS, Eller TW, Cozzens JW, et al.: Interstitial chemotherapy with drug polymer implants for the treatment of recurrent gliomas. J Neurosurg 74(3): 441–446, 1991Google Scholar
  10. 10.
    Brem H, Piantadosi S, Burger PC, Walker M, Selker R, Vick NA, Black K, Sisti M, Brem S, Mohr G, et al: Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group [see comments]. Lancet 345(8956): 1008–1012, 1995Google Scholar
  11. 11.
    Ettinger D: Evaluation of new drugs in untreated patients with small-cell lung cancer: Its time has come [comment]. J Clin Oncol 8(3): 374–377, 1990Google Scholar
  12. 12.
    Brem H, Ewend MG, Piantadosi S, Greenhoot J, Burger PC, Sisti M: The safety of interstitial chemotherapy with BCNU-loaded polymer followed by radiation therapy in the treatment of newly diagnosed malignant gliomas: Phase I trial. J Neurooncol 26(2): 111–123, 1995Google Scholar
  13. 13.
    Valtonen S, Timonen U, Toivanen P, Kalimo H, Kivipelto L, Heiskanen O, Unsgaard G, Kuurne T: Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: A randomized double-blind study. Neurosurgery 41(1): 44–48; discussion 48–49, 1997Google Scholar
  14. 14.
    Westphal M, Hilt DC, Bortey E, Delavault P, Olivares R, Wamke PC, Whittle IR, Jaaskelainen J, Ram Z: A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel® wafers) in patients with primary malignant glioma. Neuro-Oncology 5(2), 2003Google Scholar
  15. 15.
    Patchell R, Tibbs P, Walsh J, Dempsey R, Maruyama Y, Kryscio R, Markesbery W, Macdonald J, Young B: A randomized trial of surgery in the treatment of single metastases to the brain [see comments]. N Engl J Med 322(8): 494–500, 1990Google Scholar
  16. 16.
    Sawaya R, Ligon B, Bindal A, Bindal R, Hess K: Surgical treatment of metastatic brain tumors. J Neurooncol 27(3): 269–277, 1996Google Scholar
  17. 17.
    Ewend MG, Williams JA, Tabassi K, Tyler BM, Babel KM, Anderson RC, Pinn ML, Brat DJ, Brem H: Local delivery of chemotherapy and concurrent external beam radiotherapy prolongs survival in metastatic brain tumor models. Cancer Res 56(22): 5217–5223, 1996Google Scholar
  18. 18.
    Ewend M, Sampath P, Williams J, Tyler B, Brem H: Local delivery of chemotherapy prolongs survival in experimental brain metastases from breast carcinoma. Neurosurgery 43(5): 1185–1193, 1998Google Scholar
  19. 19.
    Sipos E, Tyler B, Piantadosi S, Burger P, Brem H: Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39(5): 383–389, 1997Google Scholar
  20. 20.
    Olivi A, Tatter S, Bruce J, Judy K, Engelhard H, Burak E, Hilt D, Grossman S, Fisher J, Piantadosi S: Toxicity and pharmacokinetics of interstitial BCNU administered via wafers: results of a Phase I study in patients with recurrent malignant glioma. 1999 Annual Meeting of the American Society of Clinical Oncology, 1999Google Scholar
  21. 21.
    Menei P, Venier MC, Gamelin E, Sant-Andre JP, Hayek G, Jadaud E et al.: Local and sustained delivery of 5-fluorouracil from biodegradable microspheres for the radiosensitization of glioblastoma: A pilot study. Cancer 86: 324–329, 1999Google Scholar
  22. 22.
    Brem H, Lawson HC: The development of new brain tumor therapy utilizing the local and sustained delivery of chemotherapeutic agents from biodegradable polymers. Cancer 86: 197–199, 1999Google Scholar
  23. 23.
    Rowinsky E, Burke P, Karp J, Tucker R, Ettinger D, Donehower R: Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res 49(16): 4640–4647, 1989Google Scholar
  24. 24.
    Klecker R, Jamis-Dow C, Egorin M, Erkmen K, Parker R, Collins J: Distribution and metabolism of 3H-taxol in the rat. Proc Am Assoc Cancer Res 34: 381, 1993Google Scholar
  25. 25.
    Walter KA, Cahan MA, Gur A, Tyler B, Hilton J, Colvin OM, Burger PC, Domb A, Brem H: Interstitial taxol delivered from a biodegradable polymer implant against experimental malignant glioma. Cancer Res 54(8): 2207–2212, 1994Google Scholar
  26. 26.
    Gottlieb J, Guarino A, Call J, Oliverio V, Block J: Preliminary pharmacologic and clinical evaluation of camptothecin sodium (NSC-100880). Cancer Chemother Rep 54(6): 461–470, 1970Google Scholar
  27. 27.
    Moertel C, Schutt A, Reitemeier R, Hahn R: Phase II study of camptothecin (NSC-100880) in the treatment of advanced gastrointestinal cancer. Cancer Chemother Rep 56(1): 95–101, 1972Google Scholar
  28. 28.
    Muggia F, Creaven P, Hansen H, Cohen M, Selawry O: Phase I clinical trial of weekly and daily treatment with camptothecin (NSC-100880): correlation with preclinical studies. Cancer Chemother Rep 56(4): 515–521, 1972Google Scholar
  29. 29.
    Weingart J, Thompson R, Tyler B, Colvin O, Brem H: Local delivery of the topoisomerase I inhibitor camptothecin sodium prolongs survival in the rat intracranial 9L gliosarcoma model. Int J Cancer 62(5): 605–609, 1995Google Scholar
  30. 30.
    Hannigan E, Green S, Alberts D, O TR, Surwit E: Results of a Southwest Oncology Group Phase III trial of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide in advanced ovarian cancer. Oncology 50(2): 2–9, 1993Google Scholar
  31. 31.
    Williams P, Henner W, Roman GS, Dahlborg S, Brummett R, Tableman M, Dana B, Neuwelt E: Toxicity and efficacy of carboplatin and etoposide in conjunction with disruption of the blood-brain tumor barrier in the treatment of intracranial neoplasms. Neurosurgery 37(1): 17–27; discussion 27–28, 1995Google Scholar
  32. 32.
    VonHoff D, Schilsky R, Reichert C, Reddick R, Rozencweig M, Young R, Muggia F: Toxic effects of cis-dichlorodiammine-platinum(II) in man. Cancer Treat Rep 63(9–10): 1527–1531, 1979Google Scholar
  33. 33.
    Poisson M, Pereon Y, Chiras J, Delattre J: Treatment of recurrent malignant supratentorial gliomas with carboplatin (CBDCA). J Neurooncol 10(2): 139–144, 1991Google Scholar
  34. 34.
    Olivi A, Ewend MG, Utsuki T, Tyler B, Domb AJ, Brat DJ, Brem H: Interstitial delivery of carboplatin via biodegradable polymers is effective against experimental glioma in the rat. Cancer Chemother Pharmacol 39(1–2): 90–96, 1996Google Scholar
  35. 35.
    Allen J, Helson L: High-dose cyclophosphamide chemotherapy for recurrent CNS tumors in children. J Neurosurg 55(5): 749–756, 1981Google Scholar
  36. 36.
    Judy KD, Olivi A, Buahin KG, Domb A, Epstein JI, Colvin OM, Brem H: Effectiveness of controlled release of a cyclophosphamide derivative with polymers against rat gliomas. J Neurosurg 82(3): 481–486, 1995Google Scholar
  37. 37.
    O'Reilly M, Holmgren L, Shing Y, Chen C, Rosenthal R, Moses M, Lane W, Cao Y, Sage E, Folkman J: Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma [see comments]. Cell 79(2): 315–328, 1994Google Scholar
  38. 38.
    O'Reilly M, Boehm T, Shing Y, Fukai N, Vasios G, Lane W, Flynn E, Birkhead J, Olsen B, Folkman J: Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 88(2): 277–285, 1997Google Scholar
  39. 39.
    Folkman J: Angiogenesis and angiogenesis inhibition: An overview. EXS 79: 1–8, 1997Google Scholar
  40. 40.
    Tamargo RJ, Leong KW, Brem H: Growth inhibition of the 9L glioma using polymers to release heparin and cortisone acetate. J Neurooncol 9(2): 131–138, 1990Google Scholar
  41. 41.
    Weingart J, Sipos E, Brem H: The role of minocycline in the treatment of intracranial 9L glioma. J Neurosurg 82(4): 635–640, 1995Google Scholar
  42. 42.
    Tamargo RJ, Bok RA, Brem H: Angiogenesis inhibition by minocycline. Cancer Res 51(2): 672–675, 1991Google Scholar
  43. 43.
    Guerin C, Laterra J, Masnyk T, Golub LM, Brem H: Selective endothelial growth inhibition by tetracyclines that inhibit collagenase. Biochem Biophys Res Commun 188(2): 740–745, 1992Google Scholar
  44. 44.
    Liotta L, Steeg P, Stetler-Stevenson W: Cancer metastasis and angiogenesis: An imbalance of positive and negative regulations. Cell 63: 327–336, 1991Google Scholar
  45. 45.
    Teicher B, Sotomayor E, Huang Z: Antiangiogenic agents potentiate cytotoxic cancer therapies against primary and metastatic disease. Cancer Res 52(23): 6702–6704, 1992Google Scholar
  46. 46.
    Teicher B, Dupuis N, Robinson M, Emi Y, Goff D: Antiangiogenic treatment (TNP-470/minocycline) increases tissue levels of anticancer drugs in mice bearing Lewis lung carcinoma. Oncol Res 7(5): 237–243, 1995Google Scholar
  47. 47.
    Teicher B, Holden S, Ara G, Dupuis N, Liu F, Yuan J, Ikebe M, Kakeji Y: Influence of an anti-angiogenic treatment on 9L gliosarcoma: Oxygenation and response to cytotoxic therapy. Int J Cancer 61(5): 732–737, 1995Google Scholar
  48. 48.
    Brem H, Gresser I, Grosfeld J, Folkman J: The combination of antiangiogenic agents to inhibit primary tumor growth and metastasis. J Pediatr Surg 28(10): 1253–1257, 1993Google Scholar
  49. 49.
    Mauceri H, Hanna N, Beckett M, Gorski D, Staba M, Stellato K, Bigelow K, Heimann R, Gately S, Dhanabal M, Soff G, Sukhatme V, Kufe D, Weichselbaum R: Combined effects of angiostatin and ionizing radiation in antitumour therapy. Nature 394(6690): 287–291, 1998.Google Scholar
  50. 50.
    Kinsella T, Russo A, Mitchell J, Collins J, Rowland J, Wright D, Glatstein E: A Phase I study of intravenous iododeoxyuridine as a clinical radiosensitizer. Int J Radiat Oncol Biol Phys 11(11): 1941–1946, 1985Google Scholar
  51. 51.
    Williams J, Dillehay L, Tabassi K, Sipos E, Fahlman C, Brem H: Implantable biodegradable polymers for IUdR radiosensitization of experimental human malignant glioma. J Neurooncol 32(3): 181–192, 1997Google Scholar
  52. 52.
    Williams J, Yuan X, Dillehay L, Shastri V, Brem H, Williams J: Synthetic, implantable polymers for local delivery of IUdR to experimental human malignant glioma. Int J Radiat Oncol Biol Phys 42(3): 631–639, 1998Google Scholar
  53. 53.
    Cardinale R, Dillehay L, Williams J, Tabassi K, Brem H, Lee D: Effect of interstitial and/or systemic delivery of tirapazamine on the radiosensitivity of human glioblastoma multiforme in nude mice. Radiat Oncol Investig 6(2): 63–70, 1998Google Scholar
  54. 54.
    Wiranowska M, Ransohoff J, Weingart J, Phelps C, Phuphanich S, Brem H: Interferon-containing controlled-release polymers for localized cerebral immunotherapy. J Interferon Cytokine Res 18(6): 377–385, 1998Google Scholar
  55. 55.
    Sampath P, Hanes J, DiMeco F, Tyler BM, Brat D, Pardoll DM, Brem H: Paracrine immunotherapy with Interleukin-2 and local chemotherapy is synergistic in the treatment of experimental brain tumors. Can Res 59: 2107–2114, 1999Google Scholar
  56. 56.
    Tamargo RJ, Sills AK Jr, Reinhard CS, Pinn ML, Long DM, Brem H: Interstitial delivery of dexamethasone in the brain for the reduction of peritumoral edema. J Neurosurg 74(6): 956–961, 1991Google Scholar

Copyright information

© Kluwer Academic Publishers 2004

Authors and Affiliations

  • Christopher Guerin
    • 1
  • Alessandro Olivi
    • 1
  • Jon D. Weingart
    • 1
  • H. Christopher Lawson
    • 1
  • Henry Brem
    • 1
    • 2
  1. 1.Department of NeurosurgeryJohns Hopkins University School of MedicineBaltimoreU.S.A
  2. 2.Department of OncologyJohns Hopkins University School of MedicineBaltimoreU.S.A.

Personalised recommendations